Juvenile Idiopathic arthritis (JIA) Market

Key Highlight

• The frequencies of different subtypes are 50% to 60% for oligoarthritis, 11% to 28% for RF negative polyarthritis, 2% to 7% for RF positive polyarthritis, 10% to 20% for systemic arthritis, 2% to 15% for psoriatic arthritis, 1% to 7% for enthesitis-related arthritis.
• Approximately 10% to 20% of children diagnosed with juvenile idiopathic arthritis have a rare and severe subtype known as systemic juvenile idiopathic arthritis (sJIA).
• Systemic juvenile idiopathic arthritis is more common in children between 1 to 5 years, accounting for approximately 55% of all the cases.
• KEVZARA (sarilumab) has received FDA approval for the treatment of active polyarticular juvenile idiopathic arthritis (pJIA) and is currently being evaluated in Phase II trials for systemic juvenile idiopathic arthritis (sJIA).
• The cornerstone of the treatment strategy includes nonsteroidal anti-inflammatory drugs (NSAIDs), conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs) like methotrexate, corticosteroids, and biologics with physical therapy.
• Drugs approved for the treatment of juvenile idiopathic arthritis include KEVZARA (sarilumab, Regeneron/Sanofi) RINVOQ (upadacitinib, AbbVie).
• The treatment pipeline for juvenile idiopathic arthritis reflects a significant unmet medical need. A prominent key player, Johnson & Johnson TREMFYA (guselkumab), Eli Lilly and Company/Incyte Corporation OLUMIANT (barticinib) and others.

DelveInsight’s “Juvenile Idiopathic Arthritis (JIA)– Market Insights, Epidemiology, and Market Forecast – 2034” report delivers an in-depth understanding of the JIA, historical and forecasted epidemiology as well as the JIA market trends in the US, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

Juvenile Idiopathic Arthritis (JIA) market report provides current treatment practices, emerging drugs, and market share of the individual therapies, current and forecasted 7MM JIA market size from 2020 to 2034. The report also covers current JIA treatment practice/algorithm and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.

Geography Covered

• The United States
• EU4 (Germany, France, Italy, and Spain) and the United Kingdom
• Japan

Juvenile Idiopathic Arthritis Disease Understanding and Treatment Algorithm

Juvenile Idiopathic Arthritis Overview

JIA is the most common chronic rheumatic disease in children and adolescents, characterized by persistent joint inflammation lasting at least six weeks in patients under 16 years of age, without an identifiable cause. It is an autoimmune disorder where the immune system mistakenly attacks the synovial lining of joints, leading to pain, swelling, stiffness, and potential joint damage.

There are multiple types of JIA, each with distinct features. Generally, they all share arthritic symptoms of joint pain, swelling, warmth, and stiffness that last at least 6 weeks.

• Oligoarticular juvenile idiopathic arthritis
• Polyarticular juvenile idiopathic arthritis–rheumatoid factor negative
• Polyarticular juvenile idiopathic arthritis–rheumatoid factor positive
• Enthesitis-related juvenile idiopathic arthritis
• Psoriatic juvenile idiopathic arthritis
• Systemic juvenile idiopathic arthritis
• Undifferentiated arthritis

Juvenile Idiopathic Arthritis Diagnosis

There is no single test to diagnose JIA, so doctors follow several steps. First, they perform a physical exam and review the child’s medical history to check for joint pain, swelling, and stiffness. Next, they rule out other conditions such as infections, injuries, leukemia, or connective tissue disorders. Blood tests are done to support the diagnosis and identify the JIA type these may include ESR and CRP for inflammation, ANA, rheumatoid factor (RF), anti-CCP antibodies, and HLA-B27, though normal results are common. Imaging tests like X-rays and MRI help detect fractures, tumors, or other problems and later monitor joint changes. In some cases, doctors may also take a sample of joint fluid (arthrocentesis) to rule out infection.

Juvenile Idiopathic Arthritis Treatment

Treatment of Juvenile Idiopathic Arthritis (JIA) aims to relieve pain, reduce inflammation, prevent joint damage, and maintain normal growth and function. Management usually begins with nonsteroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen or naproxen to control pain and stiffness. If symptoms persist or are severe, disease-modifying antirheumatic drugs (DMARDs) like methotrexate or leflunomide are added to slow disease progression. For children who do not respond adequately, biologic therapies are used these include TNF inhibitors (etanercept, adalimumab, golimumab), IL-1 inhibitors (anakinra, canakinumab), IL-6 inhibitors (tocilizumab, sarilumab), and T-cell modulators (abatacept). Recently, Janus kinase (JAK) inhibitors such as tofacitinib and upadacitinib have been approved as oral options for polyarticular JIA. Corticosteroids, either injected into joints or taken orally for short periods, are used to control severe flares. In addition to medication, physical and occupational therapy is essential to maintain joint mobility and muscle strength. Regular eye exams are also recommended to monitor for uveitis, a possible complication of JIA.

Further details related to diagnosis and treatment are provided in the report…

Juvenile Idiopathic Arthritis Epidemiology

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Segmented by: total prevalent cases of juvenile idiopathic arthritis, total diagnosed prevalent cases of juvenile idiopathic arthritis, age-specific cases of juvenile idiopathic arthritis, subtype- specific cases of juvenile idiopathic arthritis, total treated cases of juvenile idiopathic arthritis in the 7MM market covering the US, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan from 2020 to 2034.

• The epidemiology segment also provides the JIA epidemiology data and findings across the US, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.
• JIA is the most common rheumatic disease in children, with an estimated prevalence of 3.8 to 400 cases per 100,000 population.
• Approximately 12,000 children and young people in the UK have JIA which represents 1 child in every 1000 under the age of 16.
• Systemic juvenile idiopathic arthritis accounts for 5–15% of all children with chronic arthritis with an annual incidence of. 0.3–0.8 cases per 100,000 children under 16 years.
• Girls are more commonly affected by JIA than boys, with a ratio of approximately 1.7:1 in some populations. However, there are exceptions: Enthesitis-Related Arthritis (ERA) is more prevalent in boys, while systemic JIA affects boys and girls equally.     

Juvenile Idiopathic Arthritis Drug Chapters

The drug chapter segment of the JIA report encloses the detailed analysis of JIA mid and late-stage pipeline drugs. It also helps understand the JIA clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details of each included drug, and the latest news and press releases.

Marketed Drugs

KEVZARA (sarilumab): Regeneron/Sanofi

KEVZARA is a prescription medicine that is a fully human monoclonal antibody jointly developed and marketed by Regeneron and Sanofi. It functions as an interleukin-6 (IL-6) receptor blocker, inhibiting IL-6-mediated signaling, which is believed to play a role in inflammation associated with certain autoimmune conditions.

In June 2024, KEVZARA approved by FDA for the treatment of active polyarticular juvenile idiopathic arthritis (pJIA).

RINVOQ (upadacitinib): AbbVie

Upadacitinib is an oral, selective Janus kinase 1 (JAK1) inhibitor developed by AbbVie and marketed under the brand name RINVOQ. It is designed to modulate the JAK-STAT signaling pathway, which plays a critical role in immune system function and inflammation.

In June 2024, RINVOQ was approved for polyarticular juvenile idiopathic arthritis (pJIA) and juvenile psoriatic arthritis (JPsA) in children aged 2 years and older, marking an important advancement in JIA treatment.

Note: Deailed therapy assessment will be provided in the final report.

Emerging Drugs

TREMFYA (guselkumab): Johnson & Johnson

TREMFYA is a fully human monoclonal antibody developed by Janssen (Johnson & Johnson) that targets the p19 subunit of interleukin-23 (IL-23), a cytokine involved in the inflammatory pathways of autoimmune diseases. IL-23 plays a critical role in the differentiation and survival of Th17 cells, which produce pro-inflammatory cytokines implicated in JIA, particularly psoriatic JIA (PsJIA) and enthesitis-related arthritis (ERA) subtypes.

In July 2025, Johnson & Johnson files with US FDA to include new evidence in TREMFYA (guselkumab) label as the only IL-23 inhibitor to demonstrate significant inhibition of joint structural damage in active psoriatic arthritis.

OLUMIANT (barticinib): Eli Lilly and Company/Incyte Corporation

OLUMIANT developed by Eli Lilly and Company in collaboration with Incyte Corporation, is an oral Janus kinase (JAK) inhibitor that selectively targets JAK1 and JAK2, key mediators in cytokine signaling pathways involved in inflammatory diseases. While baricitinib is already approved for adult rheumatoid arthritis and other indications, it is not yet approved for juvenile idiopathic arthritis (JIA). Currently, it is under investigation in Phase III clinical trials (JUVE-BALM study) for pediatric patients aged 2–17 years with systemic and polyarticular JIA subtypes.

Note: Deailed therapy assessment will be provided in the final report.

Drug Class Insights

Juvenile Idiopathic Arthritis treatment involves multiple drug classes, each targeting different aspects of the disease. NSAIDs such as ibuprofen and naproxen are usually the first-line agents, offering pain and inflammation relief but with no effect on disease progression. For patients with persistent disease, conventional DMARDs, most commonly methotrexate, are used to control inflammation and prevent joint damage. If DMARDs are insufficient, biologic therapies become the cornerstone, including TNF inhibitors (etanercept, adalimumab, golimumab), IL-1 blockers (anakinra, canakinumab), IL-6 blockers (tocilizumab, sarilumab), and T-cell modulators like abatacept. Recently, JAK inhibitors such as tofacitinib, upadacitinib, and baricitinib have emerged as oral targeted options, particularly for polyarticular and systemic JIA. In severe cases or disease flares, corticosteroids are used for short-term control either orally or as intra-articular injections. This stepwise approach ensures symptom control while minimizing long-term complications and tailoring therapy to disease subtype and severity.

Juvenile Idiopathic Arthritis Market Outlook

The Juvenile Idiopathic Arthritis treatment market is steadily expanding, driven by increasing disease awareness, improved diagnostic rates, and the growing availability of advanced therapies. There has been a notable shift from traditional treatments such as NSAIDs and conventional DMARDs (e.g., methotrexate) toward biologic agents and oral targeted therapies that offer greater efficacy and convenience. Biologics targeting TNF-α, IL-1, and IL-6 pathways (such as ENBREL [Amgen/Pfizer] and ACTEMRA [Roche]) dominate the market due to their proven ability to control inflammation and prevent joint damage. Recently, JAK inhibitors like XELJANZ (Pfizer) and RINVOQ (AbbVie) have emerged as key oral options, particularly for polyarticular JIA, providing an alternative to injectable biologics.

The pipeline also features promising agents such as baricitinib (Eli Lilly/Incyte) and guselkumab (Janssen), which target novel pathways and aim to improve outcomes in refractory cases. With increasing adoption of targeted therapies and the introduction of more pediatric-friendly formulations, the JIA treatment market is expected to maintain strong growth. However, challenges remain, including high treatment costs, access disparities in low-resource regions, and the need for long-term safety data in pediatric populations.

Juvenile Idiopathic Arthritis Drugs Uptake

This section focuses on the uptake rate of potential drugs expected to be launched in the market during 2025–2034, which depends on the competitive landscape, safety, and efficacy data, along with the order of entry. It is important to understand that the key players evaluating their novel therapies in the pivotal and confirmatory trials should remain vigilant when selecting appropriate comparators to stand the greatest chance of a positive opinion from regulatory bodies, leading to approval, smooth launch, and rapid uptake. 

Juvenile Idiopathic Arthritis Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase III, Phase II, and Phase I stages. It also analyzes key players involved in developing targeted therapeutics.

Pipeline Development Activities

The report covers detailed information on collaborations, acquisitions and mergers, licensing, and patent details for JIA emerging therapies.

KOL Views

To keep up with the real-world scenario in current and emerging market trends, we take opinions from Key Industry Leaders working in the domain through primary research to fill the data gaps and validate our secondary research. Industry Experts contacted for insights on the evolving treatment landscape, patient reliance on conventional therapies, patient therapy switching acceptability, and drug uptake along with challenges related to accessibility, including Medical/scientific writers, Professors, and Others.

DelveInsight’s analyst JIA connected with 20+ KOLs to gather insights; however, interviews were conducted with 10+ KOLs in the 7MM. Centers such as University of Cincinnati, Harvard Medical School, University of Michigan, and Sarcoma Oncology Center etc., were contacted. Their opinion helps understand and validate current and emerging therapy treatment patterns or JIA market trends.

Qualitative Analysis

We perform Qualitative and market Intelligence analysis using various approaches, such as SWOT analysis and Conjoint Analysis. In the SWOT analysis, strengths, weaknesses, opportunities, and threats in terms of gaps in disease diagnosis, patient awareness, physician acceptability, competitive landscape, cost-effectiveness, and geographical accessibility of therapies are provided.

Conjoint Analysis analyzes multiple approved and emerging therapies based on relevant attributes such as safety, efficacy, frequency of administration, route of administration, and order of entry. Scoring is given based on these parameters to analyze the effectiveness of therapy.

In efficacy evaluation for dcSSc, both primary and secondary outcome measures are assessed; for instance, primary endpoints often include reduction in infarct size, improvement in tissue viability, and preservation of organ function, while secondary outcomes may involve biomarkers of oxidative stress, inflammatory response, and overall survival rates.

Further, the therapies’ safety is evaluated wherein the acceptability, tolerability, and adverse events are majorly observed, and it sets a clear understanding of the side effects posed by the drug in the trials. In addition, the scoring is also based on the probability of success, and the addressable patient pool for each therapy. According to these parameters, the final weightage score and the ranking of the emerging therapies are decided.

Market Access and Reimbursement

Antibiotics are typically prescribed for short durations, often just two weeks, and face reimbursement challenges. Government and private insurers generally use bundled payments for antibiotic treatments, covering the entire course rather than itemizing costs for the drug, administration, and other services. Hospitals receive a fixed amount, so if they manage treatment at a lower cost, they can keep the savings, improving margins. However, this system has led to poor returns for antibiotic developers, resulting in numerous company failures, bankruptcies, and low-value acquisitions in the sector.

To be continue in the final report…

Scope of the Report

• The report covers a descriptive overview of JIA, explaining its causes, signs and symptoms, pathogenesis, and currently available therapies.
• Comprehensive insight has been provided into the JIA epidemiology and treatment.
• Additionally, an all-inclusive account of both the current and emerging therapies for JIA is provided, along with an assessment of new therapies that will have an impact on the current treatment landscape.
• A detailed review of the JIA market, historical and forecasted, is included in the report, covering the 7MM drug outreach.
• The report provides an edge while developing business strategies by understanding trends shaping and driving the 7MM JIA market.

Juvenile Idiopathic Arthritis Report Insights

• Patient population
• Therapeutic approaches
• Juvenile Idiopathic Arthritis pipeline analysis
• Juvenile Idiopathic Arthritis market size and trends
• Market opportunities
• Impact of upcoming therapies

Juvenile Idiopathic Arthritis Report Key Strengths

• 10-year forecast
• 7MM coverage
• Juvenile Idiopathic Arthritis epidemiology segmentation
• Key cross competition
• Highly analyzed market
• Drugs uptake

Juvenile Idiopathic Arthritis Report Assessment

• Current treatment practices
• Unmet needs
• Pipeline product profiles
• Market attractiveness
• SWOT and conjoint analysis
• Key Questions

FAQs

• What is the historical and forecasted JIA patient pool/patient burden in the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan?
• Which combination treatment approaches will have a significant impact on the JIA drug treatment market size?
• How would the market drivers, barriers, and future opportunities affect the market dynamics and subsequent analysis of the associated trends?
• What are the current and emerging options for the treatment of JIA?
• How many companies are developing therapies for the treatment of JIA?
• What are the recent novel therapies, targets, mechanisms of action, and technologies developed to overcome the limitations of existing therapies?
• Patient acceptability in terms of preferred treatment options as per real-world scenarios?
• What are the country-specific accessibility issues of expensive, recently approved therapies?

Reasons to Buy

• The report will help in developing business strategies by understanding trends shaping and driving the JIA market.
• To understand the future market competition in the JIA market, an insightful review of the key market drivers and barriers.
• Organize sales and marketing efforts by identifying the best opportunities for JIA in the US, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.
• Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors.
• Organize sales and marketing efforts by identifying the best opportunities for the JIA market.
• To understand the future market competition in the JIA market.